Clinical Trial Update: Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma Cells [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating dendritic cells loaded with allogeneic apoptotic-necrotic melanoma cells as a vaccine in melanoma patients has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dendritic Cell Vaccine (allogeneic apoptotic-necrotic melanoma cells)

Snippet

Sponsor: José Mordoh, M.D., Ph.D. | Conditions: Melanoma | Phase 1 | Status: COMPLETED